Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00633217
First received: February 19, 2008
Last updated: October 17, 2012
Last verified: October 2012
  Purpose

The purpose of this study is to evaluate the efficacy and safety of the FSC HFA MDI in subjects with COPD. The dose of FSC HFA MDI to be evaluated corresponds to the dose of FSC DISKUS (250/50mcg twice-daily) that is indicated for the treatment of COPD associated with chronic bronchitis in the US. This study will last up to approximately 15 weeks, and subjects will visit the clinic 5 times. Subjects will be given breathing tests and will record their peak expiratory flow measurements daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The FSC HFA MDI used in this study has been approved by FDA for use in asthma while the FSC 250/50mcg DISKUS has been approved for use in asthma and COPD.


Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg
Drug: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg Twice-daily With Fluticasone Propionate/Salmeterol DISKUS 250/50mcg Twice-daily in Subjects With COPD

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug [ Time Frame: 2 hours after administration of blinded study drug; Baseline through Week 12 ] [ Designated as safety issue: No ]
    The primary efficacy analysis was mean change from baseline in 2-hour post-dose FEV1 compared between the two treatment groups at Endpoint. Change from baseline was calculated as the value at Endpoint minus the baseline value. FEV1, which is assessed using spirometry, is the maximal amount of air you can forcefully exhale in one second. Endpoint was defined as the last scheduled observation for 2 hour post-dose FEV1 during the 12-week treatment period.


Secondary Outcome Measures:
  • Mean Change From Baseline in AM Pre-dose FEV1 [ Time Frame: Measurement of FEV1 prior to study drug administration; Baseline through Week 12 ] [ Designated as safety issue: No ]
    Change from baseline was calculated as the value at Endpoint minus the baseline value. AM pre-dose FEV1, which is assessed using spirometry, is the maximum amount of air you can forcefully exhale in one second prior to taking the morning dose of study drug. Endpoint was defined as the last scheduled observation for AM pre-dose FEV1 during the 12-week treatment period.

  • Mean Change From Baseline in Peak Expiratory Flow [ Time Frame: Baseline through Week 12 ] [ Designated as safety issue: No ]
    The peak expiratory flow is a measure of the amount of air that can be pushed through the airways in a single rapid exhalation. This is measured by a peak flow meter which is a hand held device. Change from baseline was calculated as the average value over Weeks 1-12 minus the baseline value.


Enrollment: 247
Study Start Date: March 2008
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: arm 1 Drug: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg
treatment drug
Experimental: arm 2 Drug: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
treatment drug
Other Names:
  • Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
  • Fluticasone Propionate/Salmeterol DISKUS 250/50mcg

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

Subjects eligible for enrollment in the study must meet all of the following criteria:

  • Signed and dated written informed consent obtained from the subject and/or subject's legally acceptable representative prior to study participation.
  • Males or females ≥ 40 years of age.

A female is eligible to participate in this study if she is of:

  1. non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal [i.e., >1 year without menses in the absence of hormone replacement therapy]); or,
  2. child-bearing potential, has a negative pregnancy test (urine) at screen, and one of the following applies:

    • Abstinence from intercourse, or,
    • Male partner was sterile prior to the female subject's entry into the study, or,
    • Use of implants of levonorgestrel; or,
    • Injectable progesterone; or,
    • Oral contraceptive (combined or progesterone only), contraceptive patch, vaginal ring; or,
    • Any intrauterine device (IUD) with published data showing that the highest expected failure rate is less than 1% per year (e.g., Paragard), or,
    • Double barrier technique simultaneously using two of the following: spermicide, male condom, diaphragm, or female condom

      • An established clinical history of COPD (including chronic bronchitis and/or emphysema) in accordance with the following definition by the American Thoracic Society:

COPD is a preventable and treatable disease state characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences [Celli, 2004].

  • A post-albuterol FEV1/FVC ratio of ≤ 0.70
  • A post-albuterol FEV1 ≥ 0.70L and ≤ 70% of predicted normal OR a post-albuterol FEV1 of ≤ 0.70L and ≥40% of predicted normal but still ≤70% of predicted normal based on NHANES III reference values [Hankinson, 1999].
  • Current or previous smokers with a cigarette smoking history of ≥ 10 pack-years. [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 10 pack-years is equal to 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years]. Former-smokers are defined as subjects who have discontinued smoking for ≥ 6 months prior to Visit 1. Subjects who decide to stop smoking at Visit 1 will not be eligible for participation in the study.

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  • A current diagnosis of asthma.
  • Any clinically significant and uncontrolled disease, including but not limited to the following: neurological, psychiatric, renal, immunological, endocrine/metabolic (including uncontrolled diabetes, hypokalemia or thyroid disease), cardiovascular, neuromuscular, hepatic, gastric, or hematological abnormalities, or peripheral vascular disease. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would affect the efficacy analysis if the disease/condition exacerbated during the study.
  • A respiratory diagnosis other than COPD (e.g., lung cancer, bronchiectasis, sarcoidosis, tuberculosis, lung fibrosis), including subjects with a diagnosis of alpha-1-antitrypsin deficiency. Allergic rhinitis is not exclusionary.
  • An abnormal and clinically significant chest x-ray or computed tomography (CT) scan not believed to be due to the presence of COPD. A chest x-ray must be taken if the subject has not had one within 6 months of Visit 1.
  • An abnormal and clinically significant 12-lead electrocardiogram (ECG). For the purposes of this study, an abnormal ECG is defined as a 12-lead tracing which is interpreted with (but not limited to) any of the following:

    • Myocardial ischemia
    • Clinically significant conduction abnormalities (e.g., left bundle branch block, Wolff-Parkinson-White syndrome)
    • Clinically significant arrhythmias (e.g., atrial fibrillation, ventricular tachycardia) The study investigator will determine the clinical significance of any ECG abnormality and determine if a subject is precluded from entering the study.
  • Previously diagnosed cancer unless it is in complete clinical remission (no evidence of any tumor burden) at Visit 1. Localized carcinomas of the skin that have been resected for cure are not considered exclusionary.
  • Any immediate or delayed hypersensitivity to any beta-agonist, sympathomimetic drug, or intranasal, inhaled, or oral corticosteroid including any components of the formulations (e.g. lactose or milk protein).
  • Initiation of systemic beta-blocker medications within 30 days of Visit 1.
  • Use of products containing the protease inhibitor ritonavir (Norvir, Kaletra).
  • Use of the following medications within the defined times prior to Visit 1:

Medication (Exclusion Prior to Visit 1) Short-acting beta-agonists (e.g., albuterol) (6 hours) Ipratropium (6 hours) Ipratropium/albuterol combination product (6 hours) Oral beta-agonists (48 hours) Salmeterol and formoterol (48 hours) Theophylline preparations (48 hours) Tiotropium (48 hours) Long-acting beta-agonist/inhaled corticosteroid combination products (e.g., ADVAIR™ or Symbicort) (30 days) Inhaled corticosteroids (30 days) Oral or parenteral corticosteroids (30 days) Any investigational drug (30 days)

  • Lung resection surgery (e.g., lung volume reduction surgery, or lobectomy) within 1 year of Visit 1.
  • A COPD exacerbation and/or infection of the upper or lower respiratory tract requiring treatment with systemic (oral or parenteral) corticosteroids and/or antibiotics that has not resolved within 30 days of Visit 1
  • A COPD exacerbation that resulted in hospitalization that has not resolved within 3 months of Visit 1.
  • Use of nocturnal positive pressure [e.g., continuous positive airway pressure or bi-level positive airway pressure].
  • A body mass index (BMI) of ≥ 40kg/m².
  • Subject is a study investigator, sub-investigator, study coordinator, or employee of a participating investigator or immediate family members of the aforementioned.
  • Any intellectual deficiency including illiteracy, history of substance abuse in the two years prior to Visit 1 (including drug and alcohol), or other conditions, which will limit the validity of informed consent to participate in the study.
  • Supplemental oxygen, with the following exceptions:

    • Use at high altitude (> 5000 feet) provided subject does not require a flow rate of > 2 L/minute
    • Use for exertion provided subject does not require > 2 hours per day of oxygen and does not require a flow rate of > 2L/minute
    • Use for nocturnal therapy provided subject does not require a flow rate of > 2L/minute
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00633217

Locations
United States, Alabama
GSK Investigational Site
Jasper, Alabama, United States, 35501
GSK Investigational Site
Mobile, Alabama, United States, 36608
United States, Louisiana
GSK Investigational Site
Lafayette, Louisiana, United States, 70503
GSK Investigational Site
New Orleans, Louisiana, United States, 70115
GSK Investigational Site
Sunset, Louisiana, United States, 70584
United States, Missouri
GSK Investigational Site
St. Charles, Missouri, United States, 63301
United States, North Carolina
GSK Investigational Site
Elizabeth City, North Carolina, United States, 27909
United States, Pennsylvania
GSK Investigational Site
Erie, Pennsylvania, United States, 16508
United States, South Carolina
GSK Investigational Site
Charleston, South Carolina, United States, 29406-7108
GSK Investigational Site
Gaffney, South Carolina, United States, 29340
GSK Investigational Site
Greenville, South Carolina, United States, 29615
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303
GSK Investigational Site
Union, South Carolina, United States, 29309
United States, Texas
GSK Investigational Site
Corsicana, Texas, United States, 75110
United States, Virginia
GSK Investigational Site
Richmond, Virginia, United States, 23229
United States, West Virginia
GSK Investigational Site
Morgantown, West Virginia, United States, 26505
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications:
Koser A, Westerman J, Sharma S, Emmett A, Crater GD. Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. Open Respir Med J. 2010 Oct 21;4:86-91.

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00633217     History of Changes
Other Study ID Numbers: 111117
Study First Received: February 19, 2008
Results First Received: October 22, 2009
Last Updated: October 17, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
DISKUS
Salmeterol
Fluticasone Propionate
Chronic Obstructive Pulmonary Disease (COPD)
Hydroflouroalkane
COPD
HFA MDI

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Albuterol
Fluticasone
Salmeterol
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Dermatologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Respiratory System Agents
Therapeutic Uses
Tocolytic Agents

ClinicalTrials.gov processed this record on November 20, 2014